Back D - Search Results

1

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

Taylor S, Jayasuriya A, Fisher M, Allan S, Wilkins E, Gilleran G, Heald L, Fidler S, Owen A, Back D, Smit E. Taylor S, et al. Among authors: back d. J Antimicrob Chemother. 2012 Mar;67(3):675-80. doi: 10.1093/jac/dkr491. Epub 2011 Dec 14. J Antimicrob Chemother. 2012. PMID: 22169189

2

Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.

Taylor S, Little J, Halifax K, Drake S, Back D. Taylor S, et al. Among authors: back d. J Antimicrob Chemother. 2000 May;45(5):716-7. doi: 10.1093/jac/45.5.716. J Antimicrob Chemother. 2000. PMID: 10797104 No abstract available.

3

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.

Mackie NE, Fidler S, Tamm N, Clarke JR, Back D, Weber JN, Taylor GP. Mackie NE, et al. Among authors: back d. HIV Med. 2004 May;5(3):180-4. doi: 10.1111/j.1468-1293.2004.00208.x. HIV Med. 2004. PMID: 15139985 Free article.

4

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.

Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S, Back DJ. Isaac A, et al. J Antimicrob Chemother. 2004 Aug;54(2):498-502. doi: 10.1093/jac/dkh357. Epub 2004 Jul 14. J Antimicrob Chemother. 2004. PMID: 15254024 Clinical Trial.

5

Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.

Owen A, Chandler B, Back DJ, Khoo SH. Owen A, et al. Antivir Ther. 2004 Oct;9(5):819-21. Antivir Ther. 2004. PMID: 15535420

6

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A. Boffito M, et al. Among authors: back d. J Antimicrob Chemother. 2005 Apr;55(4):542-5. doi: 10.1093/jac/dki043. Epub 2005 Feb 18. J Antimicrob Chemother. 2005. PMID: 15722388

7

The implications of P-glycoprotein in HIV: friend or foe?

Owen A, Chandler B, Back DJ. Owen A, et al. Fundam Clin Pharmacol. 2005 Jun;19(3):283-96. doi: 10.1111/j.1472-8206.2005.00324.x. Fundam Clin Pharmacol. 2005. PMID: 15910652 Review.

8

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Almond LM, et al. Among authors: back dj. J Antimicrob Chemother. 2005 Oct;56(4):738-44. doi: 10.1093/jac/dki308. Epub 2005 Sep 1. J Antimicrob Chemother. 2005. PMID: 16141277

9

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Back DJ, Owen A, Khoo SH. Back DJ, et al. Clin Pharmacokinet. 2006;45(2):213-4; author reply 214-5. doi: 10.2165/00003088-200645020-00006. Clin Pharmacokinet. 2006. PMID: 16485918 No abstract available.

10

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: back d. J Antimicrob Chemother. 2006 Nov;58(5):1009-16. doi: 10.1093/jac/dkl379. Epub 2006 Sep 19. J Antimicrob Chemother. 2006. PMID: 16984898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters